Abstract
Dupuytren’s disease is a progressive, benign fibroproliferative disorder of the hands that can lead to debilitating hand contractures. Once symptomatic, treatment involves either surgical intervention, specifically fasciectomy or percutaneous needle aponeurotomy, or enzymatic degradation with clostridial collagenase. Currently, collagenase is the only pharmacotherapy that has been approved for the treatment of Dupuytren’s contracture. There is a need for a pharmacotherapeutic that can be administered to limit disease progression and prevent recurrence after treatment. Targeting the underlying fibrotic pathophysiology is critical. The authors propose a novel target to be considered in Dupuytren’s disease – cell communication network factor 2/connective tissue growth factor (CCN2/CTGF) – an established mediator of musculoskeletal tissue fibrosis.
Recommended Citation
Lambi, Alex G.; Ryan Dahlberg; Tomas Holy; Joseph T. Tarr; Deana Mercer; Steven N. Popoff; and Mary F. Barbe. "Let’s Focus on the Fibrosis: Targeting CCN2 in Dupuytren’s Disease." Western Journal of Orthopaedics 12, 1 (2023). https://digitalrepository.unm.edu/wjo/vol12/iss1/4